GlaxoSmithKline bails on Basilea’s eczema drug, nixing a $72M payout

Damian Garde

has abandoned its plot to win FDA approval for an treatment from Basilea Pharmaceutica, ending a project that could have paid its partner about $ 72 million plus royalties.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS